1887
Volume 2022, Issue 4
  • ISSN: 0253-8253
  • EISSN: 2227-0426

Abstract

Background: There is an increasing number of COVID-19-related Rhino-orbital-cerebral mucormycosis (ROCM), especially from India.

Objectives: To evaluate the demographic, clinical, radiological, and outcome of the COVID-19-related ROCM cases in a single center.

Materials and Methods: The medical records of the patients with COVID-19-related ROCM were retrospectively reviewed. The study covered 22 months duration from March 2020 to December 2021 in Imam Hussain Medical City, Karbala city, Iraq.

Results: Of the 14 patients with COVID-19-related ROCM, there were 71.4% males with a male-to-female ratio of 2.5:1. The median age was 61 years (age range: 27-80 years). There were 42.9% of patients with a history of being a current smoker. All patients had a history of DM, and 57.1% of patients had a history of hypertension. All patients were without a history of the previous episode of COVID-19 or taking the vaccine. The median duration from the COVID-19 diagnosis to the diagnosis of ROCM was 19 days (duration range of 10-40 days). Most of the cases were of severe type (57.1%). All of the patients were taking corticosteroid and oxygen therapy. Nasal obstruction, nasal discharge, cheek swelling, and necrotic tissue were clinical features in all patients. The majority of the cases were on the left side (71.4%). Stage 3 was found in 42.9%. Amphotericin B was used for all patients and surgical debridement in 13 cases. Five patients have died (35.7%).

Conclusion: COVID-19-related ROCM is an aggressive disease associated with a high mortality rate of 35.7%. Early diagnosis and on-time initiation of treatment are recommended to get the best outcome.

Loading

Article metrics loading...

/content/journals/10.5339/qmj.2022.47
2022-10-06
2022-12-07
Loading full text...

Full text loading...

/deliver/fulltext/qmj/2022/4/qmj.2022.47.html?itemId=/content/journals/10.5339/qmj.2022.47&mimeType=html&fmt=ahah

References

  1. Rashid RA, Alaqeedy AA, Al-Ani RM. Parosmia Due to COVID-19 Disease: A 268 Case Series. Indian J Otolaryngol Head Neck Surg. 2021 May; 23:18.
    [Google Scholar]
  2. Yaseen NK, Al-Ani RM, Ali Rashi R. COVID-19-related sudden sensorineural hearing loss. Qatar Med J. 2021 Oct 25;; 2021:3: 58.
    [Google Scholar]
  3. Sharma S, Grover M, Bhargava S, Samdani S, Kataria T. Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum. J Laryngol Otol. 2021 May; 135:5:442447.
    [Google Scholar]
  4. Prakash H, Ghosh AK, Rudramurthy SM, et al., A prospective multicenter study on mucormycosis in India: Epidemiology diagnosis, an treatment. Med Mycol. 2019;; 57:4:395402.
    [Google Scholar]
  5. Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. Diabetes Metab Syndr Clin Res Rev. 2021; 15:4:102146.
    [Google Scholar]
  6. Jeong W, Keighley C, Wolfe R, et al., The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect. 2019; 25:1:2634.
    [Google Scholar]
  7. Mitra S, Janweja M, Sengupta A. Post-COVID-19 rhino-orbito-cerebral mucormycosis: a new addition to challenges in pandemic control. Eur Arch Otorhinolaryngol. 2022 May; 279:5:24172422.
    [Google Scholar]
  8. Sen M, Honavar SG, Bansal R, et al., Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India-Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), Report 1. Indian J Ophthalmol. 2021; 69:7:1670.
    [Google Scholar]
  9. Pemán J, Ruiz-Gaitán A, García-Vidal C, et al., Fungal co-infection in COVID-19 patients: Should we be concerned? Rev Iberoam Micol. 2020; 37:2:4146.
    [Google Scholar]
  10. Ahmadikia K, Hashemi SJ, Khodavaisy S, et al., The double-edged sword of systemic corticosteroid therapy in viral pneumonia: A case report and comparative review of influenza-associated mucormycosis versus COVID-19 associated mucormycosis. Mycoses. 2021; 64:8:798808.
    [Google Scholar]
  11. Moorthy A, Gaikwad R, Krishna S, et al., SARS-CoV-2 uncontrolled diabetes and corticosteroids-an unholy trinity in invasive fungal infections of the maxillofacial region? A retrospective multi-centric analysis. J Maxillofac Oral Surg. 2021; 20:3:425418.
    [Google Scholar]
  12. Janjua OS, Shaikh MS, Fareed MA, et al., Dental and Oral Manifestations of COVID-19 Related Mucormycosis: Diagnoses, Management Strategies and Outcomes. J Fungi. 2021; 8:(1):44.
    [Google Scholar]
  13. Guarner J, Brandt ME. Histopathologic diagnosis of fungal infections in the 21st century. Clin Microbiol Rev. 2011; 24:2:247280.
    [Google Scholar]
  14. Walsh TJ, Gamaletsou MN, McGinnis MR, Hayden RT, Kontoyiannis DP. Early clinical and laboratory diagnosis of invasive pulmonary extrapulmonary, an disseminated mucormycosis (zygomycosis). Clin Infect Dis. 2012 Feb; 54:Suppl 1:60S55.
    [Google Scholar]
  15. Al-Abbasi AM, Abdil-Wahab A, Al-Jezani AR, Hashim HS, Al-Temimi DA. RHINO-ORBITO-CEREBRAL MUCORMYCOSIS IN BASRAH-IRAQ. Basrah J Surg. 2017; 23:2:914.
    [Google Scholar]
  16. Farid HA, Hashim AR, Hasrat NH. Rhinocerebral mucormycosis as a COVID-19-related complication: a case report from Basra City Southern Iraq. J Glob Sci Res. 2021; 6:5:13691374.
    [Google Scholar]
  17. Nalbandian A, Sehgal K, Gupta A, et al., Post-acute COVID-19 syndrome. Nat Med. 2021; 27:4:601615.
    [Google Scholar]
  18. Qiu C, Cui C, Hautefort C, et al.,  < ? covid19?> Olfactory and gustatory dysfunction as an early identifier of COVID-19 in adults and children: an international multicenter study. Otolaryngol Neck Surg. 2020; 163:4:714721.
    [Google Scholar]
  19. Honavar SG. Code mucor: guidelines for the diagnosis staging an management of rhino-orbito-cerebral mucormycosis in the setting of COVID-19. Indian J Ophthalmol. 2021; 69:6:1361.
    [Google Scholar]
  20. Patel A, Kaur H, Xess I, et al., A multicentre observational study on the epidemiology, risk factors, management and outcomes of mucormycosis in India. Clin Microbiol Infect. 2020; 26:7:944e949.
    [Google Scholar]
  21. Chander J, Kaur M, Singla N, et al., Mucormycosis: battle with the deadly enemy over a five-year period in India. J fungi. 2018; 4:2:46.
    [Google Scholar]
  22. Prakash H, Chakrabarti A. Global epidemiology of mucormycosis. J Fungi. 2019; 5:1:26.
    [Google Scholar]
  23. Alloush TK, Mansour O, Alloush AT, et al., Rhino-orbito-cerebral mucormycosis during the COVID-19 third wave in 2021: an Egyptian preliminary report from a single tertiary hospital. Neurol Sci. 2022; 43:2:799809.
    [Google Scholar]
  24. Ezeokoli OT, Gcilitshana O, Pohl CH. Risk factors for fungal co-infections in critically ill COVID-19 patients, with a focus on immunosuppressants. J Fungi. 2021; 7:7:545.
    [Google Scholar]
  25. Rawson TM, Moore LSP, Zhu N, et al., Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis. 2020; 71:9:24592468.
    [Google Scholar]
  26. Arora R, Goel R, Khanam S, et al., Rhino-Orbito-Cerebral-Mucormycosis During the COVID-19 Second Wave in 2021–A Preliminary Report from a Single Hospital. Clin Ophthalmol (Auckland NZ). 2021; 15::3505.
    [Google Scholar]
  27. Pakdel F, Ahmadikia K, Salehi M, et al., Mucormycosis in patients with COVID-19: a cross-sectional descriptive multicentre study from Iran. Mycoses. 2021; 64:10:12381252.
    [Google Scholar]
  28. Alloush TK, Mansour O, Alloush AT, et al., Rhino-orbito-cerebral mucormycosis during the COVID-19 third wave in 2021: an Egyptian preliminary report from a single tertiary hospital. Neurol Sci. 2021::11.
    [Google Scholar]
  29. Jin J-M, Bai P, He W, et al., Gender differences in patients with COVID-19: focus on severity and mortality. Front public Heal. 2020:152.
    [Google Scholar]
  30. Ruggieri A, Gagliardi MC. Gender differences in COVID-19: some open questions. Ital J Gender-Specific Med. 2020; 6:2:4950.
    [Google Scholar]
  31. Brunet K, Rammaert B. Mucormycosis treatment: Recommendations latest advances and perspectives. J Mycol Med. 2020; 30:3:101007.
    [Google Scholar]
  32. Skiada A, Lanternier F, Groll AH, et al., Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica. 2013; 98:4:492.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/qmj.2022.47
Loading
/content/journals/10.5339/qmj.2022.47
Loading

Data & Media loading...

  • Article Type: Research Article
Keyword(s): COVID-19COVID-19 complicationsMucormycosis and Rhino-orbital-cerebral mucormycosis
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error